Australia markets open in 1 hour 4 minutes

AdAlta Limited (1AD.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0280+0.0010 (+3.70%)
At close: 04:10PM AEST

AdAlta Limited

2 Park Drive
Unit 15
Bundoora, VIC 3083
61 3 9479 5159

Full-time employees10

Key executives

NameTitlePayExercisedYear born
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.CEO, MD & Director398.86kN/AN/A
Mr. Angus Tester Ph.D.Senior Director of OperationsN/AN/AN/A
Ms. Janette DixonHead of Business DevelopmentN/AN/AN/A
Mr. Cameron Jones C.A.Company SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.

Corporate governance

AdAlta Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.